<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11437400</article-id><article-id pub-id-type="pmcid-ver">PMC11437400.1</article-id><article-id pub-id-type="pmcaid">11437400</article-id><article-id pub-id-type="pmcaiid">11437400</article-id><article-id pub-id-type="pmid">39339952</article-id><article-id pub-id-type="doi">10.3390/v16091476</article-id><article-id pub-id-type="publisher-id">viruses-16-01476</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9178-9881</contrib-id><name name-style="western"><surname>Chang</surname><given-names initials="JY">Jane Y.</given-names></name><xref rid="af1-viruses-16-01476" ref-type="aff">1</xref><xref rid="c1-viruses-16-01476" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Balch</surname><given-names initials="C">Curt</given-names></name><xref rid="af2-viruses-16-01476" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1739-0389</contrib-id><name name-style="western"><surname>Oh</surname><given-names initials="HS">Hyung Suk</given-names></name><xref rid="af3-viruses-16-01476" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Garbuglia</surname><given-names initials="AR">Anna Rosa</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>La Frazia</surname><given-names initials="S">Simone</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01476"><label>1</label>Ascendant Biotech Inc., Foster City, CA 94404, USA</aff><aff id="af2-viruses-16-01476"><label>2</label>Bioscience Advising, Cincinnati, OH 45208, USA; <email>curt.balch@gmail.com</email></aff><aff id="af3-viruses-16-01476"><label>3</label>Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA; <email>hyungsuk_oh@hms.harvard.edu</email></aff><author-notes><corresp id="c1-viruses-16-01476"><label>*</label>Correspondence: <email>janechang@ascendantbiotech.com</email></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2024</year></pub-date><volume>16</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">471660</issue-id><elocation-id>1476</elocation-id><history><date date-type="received"><day>11</day><month>8</month><year>2024</year></date><date date-type="rev-recd"><day>11</day><month>9</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>17</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-29 16:25:13.610"><day>29</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-16-01476.pdf"/><abstract><p>Herpes simplex virus (HSV) has coevolved with <italic toggle="yes">Homo sapiens</italic> for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or therapeutic vaccine for HSV remains elusive. In this review, we independently screened PubMed, EMBASE, Medline, and Google Scholar for clinically relevant articles on HSV vaccines. We identified 12 vaccines from our literature review and found promising candidates across various classes, including subunit vaccines, live vaccines, DNA vaccines, and mRNA vaccines. Notably, several vaccines&#8212;SL-V20, HF10, VC2, and mRNA-1608&#8212;have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. Additionally, several other vaccines such as GEN-003 (a subunit vaccine from Genocea), HerpV (a subunit vaccine from Agenus), 0&#916;NLS/RVx201 (a live-attenuated replication-competent vaccine from Rational Vaccines), HSV 529 (a replication-defective vaccine from Sanofi Pasteur), and COR-1 (a DNA-based vaccine from Anteris Technologies) have demonstrated potential in clinical trials. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections.</p></abstract><kwd-group><kwd>herpes simplex virus type 1</kwd><kwd>live-attenuated vaccines</kwd><kwd>mRNA vaccine</kwd><kwd>replication-defective strains</kwd><kwd>interferon response</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01476"><title>1. Introduction</title><p>Herpes simplex virus (HSV) ranks among the oldest and most successful vertebrate pathogens, noted for its ubiquity, lifelong persistence in hosts, and evolutionary codivergence spanning hundreds of millions of years [<xref rid="B1-viruses-16-01476" ref-type="bibr">1</xref>]. The World Health Organization (WHO) estimates that 3.7 and 0.5 billion people worldwide are infected with HSV-1 and HSV-2, respectively [<xref rid="B2-viruses-16-01476" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01476" ref-type="bibr">3</xref>]. In the United States alone, annual expenditure on HSV treatment reaches USD 8 billion, not counting productivity losses [<xref rid="B4-viruses-16-01476" ref-type="bibr">4</xref>]. HSV, a large, enveloped DNA virus, infects epithelial surfaces lytically and establishes lifelong latency in sensory neurons. Despite often remaining asymptomatic during latency, HSV can cause recurrent outbreaks manifesting as epithelial blisters and cold sores, with severe complications including encephalitis, meningitis, and vision-threatening herpetic keratitis, the leading cause of infectious blindness [<xref rid="B2-viruses-16-01476" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01476" ref-type="bibr">3</xref>].</p><p>Efforts to find a permanent solution to HSV have been a focus of scientific and medical research for over a century, with the first published vaccine attempt dating back to 1926 [<xref rid="B5-viruses-16-01476" ref-type="bibr">5</xref>]. However, as of 2024, no effective functional cure, vaccine, or method to eliminate lifelong infection has been developed. The widespread prevalence of HSV poses significant challenges and offers insights into superinfections, such as those involving HIV. It is estimated that a successful HSV vaccine could reduce HIV incidence by 30&#8211;40% over 20 years [<xref rid="B6-viruses-16-01476" ref-type="bibr">6</xref>]. Additionally, due to HSV&#8217;s infection of peripheral and CNS neurons, it has been linked to neurodegenerative diseases like Alzheimer&#8217;s disease [<xref rid="B7-viruses-16-01476" ref-type="bibr">7</xref>,<xref rid="B8-viruses-16-01476" ref-type="bibr">8</xref>].</p><p>Addressing the economic and medical challenges posed by HSV, including its increasing incidence, underscores the urgent need for the development of both prophylactic and therapeutic vaccines. Recent innovative approaches, such as nanotechnology and genomic editing, also show promise. In 2016, the WHO&#8217;s Product Development for Vaccines Advisory Committee emphasized the critical need for HSV vaccines for global use. Concurrently, the Global Health Sector Strategy for Sexually Transmitted Infections identified vaccine development as a key innovation for the future control of sexually transmitted infections [<xref rid="B9-viruses-16-01476" ref-type="bibr">9</xref>].</p></sec><sec sec-type="methods" id="sec2-viruses-16-01476"><title>2. Methods</title><p>Two authors (J.Y.C. and C.B.) conducted a comprehensive literature search using PubMed, EMBASE, Medline, and Google Scholar with the search terms &#8220;vaccines and HSV&#8221;, &#8220;vaccines and herpes simplex virus&#8221;, &#8220;herpes simplex virus immunization&#8221;, and &#8220;HSV immunization&#8221;. They independently screened the abstracts for clinically relevant articles. Any disagreements regarding the inclusion of articles for specific therapeutic and preventive approaches were discussed and resolved prior to their incorporation into the review, ensuring relevance and historical support.</p><sec id="sec2dot1-viruses-16-01476"><title>2.1. HSV Life Cycle, Pathogenesis, and Immune Evasion</title><p>HSV-1 and HSV-2, primarily responsible for infections of the orofacial and genital mucosal surfaces, respectively, share a common structure. Each virus consists of a large, double-stranded, linear DNA genome (encoding over 84 genes) housed within an icosahedral protein cage, or nucleocapsid, which is enveloped by a lipid bilayer [<xref rid="B10-viruses-16-01476" ref-type="bibr">10</xref>]. The nucleocapsid is connected to the envelope by &#8220;teguments&#8221;, unique structural proteins encoded by the virus. The entire particle is referred to as a &#8220;virion&#8221; (<xref rid="viruses-16-01476-f001" ref-type="fig">Figure 1</xref>). HSV genes encode various proteins essential for forming the capsid, teguments, and viral envelope, as well as for controlling the replication and infectivity of the virus. The genomes of HSV-1 and HSV-2 are complex and divided into two segments: unique L (UL) and unique S (US). These segments encode 57 UL and 12 US single-copy genes separated by repeated genes [<xref rid="B10-viruses-16-01476" ref-type="bibr">10</xref>,<xref rid="B11-viruses-16-01476" ref-type="bibr">11</xref>]. The UL and unique US regions are each flanked by internal and terminal inverted repeats (<xref rid="viruses-16-01476-f001" ref-type="fig">Figure 1</xref>). Several key genes are located in repeat regions and are diploid.</p><p>The transcription of HSV genes is catalyzed by RNA polymerase II of the infected host [<xref rid="B12-viruses-16-01476" ref-type="bibr">12</xref>]. HSV follows a cascade gene expression pattern, progressing from immediate early (IE) to early (E) and late (L) periods. IE genes, which are expressed first, encode proteins that regulate the expression of E and L viral genes. E genes encode enzymes involved in DNA replication and the biosynthesis of envelope glycoproteins. The expression of L genes, which occurs last, predominantly encodes proteins that form the virion particle [<xref rid="B10-viruses-16-01476" ref-type="bibr">10</xref>], ultimately leading to the egress of mature virions from the host cell.</p><p>The entry of HSV into cells requires the coordinated interaction of a variety of glycoproteins found on the virion surface [<xref rid="B13-viruses-16-01476" ref-type="bibr">13</xref>]. The initial attachment of a virus to a host cell is mediated by multiple viral glycoproteins and various binding receptors [<xref rid="B13-viruses-16-01476" ref-type="bibr">13</xref>]. Although the fusion machinery is similar for all herpesviruses, each species uses distinct receptors and receptor-binding glycoproteins. Key glycoproteins targeted by HSV vaccines include glycoprotein C (gC), glycoprotein D (gD), and glycoprotein E (gE). gD, which is essential for virion infectivity, is the required receptor-binding protein for most alphaherpesviruses. gD binds to three classes of receptors, including nectins, herpesvirus entry mediators, and a modified form of heparan sulfate [<xref rid="B13-viruses-16-01476" ref-type="bibr">13</xref>]. Nectin-2 mediates the entry of some HSV-1 and HSV-2 strains, while derivatives of heparan sulfate can also serve as entry receptors for HSV-1 [<xref rid="B13-viruses-16-01476" ref-type="bibr">13</xref>]. Meanwhile, gC, which is required for the efficient binding of virions to the cell surface, is implicated in the infection process [<xref rid="B14-viruses-16-01476" ref-type="bibr">14</xref>]. Finally, gE binds the Fc domain of immunoglobulin G, contributing to HSV immune evasion [<xref rid="B15-viruses-16-01476" ref-type="bibr">15</xref>].</p><p>Initial expression of the five IE genes, ICP0, ICP4, ICP22, ICP 27, and ICP 47, is driven by the viral transcription factor VP16, a virion tegument protein [<xref rid="B16-viruses-16-01476" ref-type="bibr">16</xref>]. HSV-1 encodes its own RING-finger E3 ubiquitin ligase in the form of infected cell polypeptide 0 (ICP0), which directly interfaces with component proteins of the ubiquitin pathway to inactivate host immune defenses [<xref rid="B17-viruses-16-01476" ref-type="bibr">17</xref>]. Consequently, ICP0 plays a critical role in the infectious cycle of HSV-1, which is required to promote the onset of lytic infection and the reactivation of viral genomes from latency [<xref rid="B17-viruses-16-01476" ref-type="bibr">17</xref>]. Furthermore, mutations that inactivate ICP0 render HSV-1 highly sensitive to interferon inhibition [<xref rid="B18-viruses-16-01476" ref-type="bibr">18</xref>].</p><p>The IE gene product ICP4 (encoded by <italic toggle="yes">RS1</italic>) is one of the major regulatory factors required to efficiently activate the transcription of early and late viral genes during HSV infection [<xref rid="B19-viruses-16-01476" ref-type="bibr">19</xref>]. ICP4 is a transcriptional regulator that plays a prominent role within this cascade [<xref rid="B20-viruses-16-01476" ref-type="bibr">20</xref>]. It carries out these functions by interacting with DNA and modulating host cellular RNA polymerase II activity on viral genes [<xref rid="B21-viruses-16-01476" ref-type="bibr">21</xref>]. ICP27 (encoded by <italic toggle="yes">UL54</italic>) is another essential IE protein that upregulates early and late viral genes [<xref rid="B16-viruses-16-01476" ref-type="bibr">16</xref>]. ICP27 performs multiple functions during HSV-1 infection, many of which involve post-transcriptional effects on viral and cellular mRNAs [<xref rid="B16-viruses-16-01476" ref-type="bibr">16</xref>]. ICP4 and ICP27 interaction is required to properly incorporate ICP4 into the virion. ICP22 (encoded by <italic toggle="yes">US1</italic>), necessary for efficient acute replication in mice, appears to be the least studied of the five IE proteins [<xref rid="B22-viruses-16-01476" ref-type="bibr">22</xref>].</p><p>Other important HSV proteins include ICP8 (encoded by <italic toggle="yes">UL29</italic>), a replicative single-stranded DNA binding protein that forms filaments and binds cooperatively to single-stranded DNA. ICP8 interacts with other viral and cellular proteins to promote viral DNA replication [<xref rid="B23-viruses-16-01476" ref-type="bibr">23</xref>]. Tegument proteins are a group of viral structural components that play an important role in viral gene replication and virion assembly [<xref rid="B24-viruses-16-01476" ref-type="bibr">24</xref>]. Several HSV-1 tegument proteins have been identified as being associated with viral DNA transport into and out of the nucleus for viral assembly [<xref rid="B24-viruses-16-01476" ref-type="bibr">24</xref>]. The latency-associated transcript (LAT) is an unusual region of the HSV genome, located in the long repeat region (TR<sub>L</sub> and IR<sub>L</sub>) (<xref rid="viruses-16-01476-f001" ref-type="fig">Figure 1</xref>B), which is not silenced by viral genes during latency. Genetic studies involving deletions and mutations within the LAT promoter and 5&#8242; exon-coding region have yielded a multitude of phenotypes associated with anti-apoptosis, neuronal tropism, reactivation, leakiness of lytic gene transcription during latency, and histone H3 methylation [<xref rid="B25-viruses-16-01476" ref-type="bibr">25</xref>]. Finally, the mechanism of action of acyclovir requires phosphorylation by the viral thymidine kinase (encoded by <italic toggle="yes">UL23</italic>) to yield acyclovir monophosphate, which then eventually induces the repression of viral replication, through reduced DNA polymerase activity [<xref rid="B26-viruses-16-01476" ref-type="bibr">26</xref>].</p><p>Productive infection results in the formation of vesicular lesions in the mucosal epithelia. This is followed by viral spread to the axonal terminals of peripheral neurons, retrograde transport toward the cell body, and the establishment of a latent infection that typically persists for the life of the host. Reactivation leads to the anterograde transport of viral progeny and the reinfection of the innervated epithelial tissues [<xref rid="B27-viruses-16-01476" ref-type="bibr">27</xref>]. Reactivation can be triggered by cellular (nutritional or oxidative stress) or environmental (emotional stress, fever, UV exposure, hormonal changes, surgery, cranial trauma, etc.) factors. However, it remains unclear whether these triggers act directly on infected neurons or through systemic functions [<xref rid="B27-viruses-16-01476" ref-type="bibr">27</xref>].</p></sec><sec id="sec2dot2-viruses-16-01476"><title>2.2. HSV Defense Mechanisms to Evade Immune Responses</title><p>HSV has developed numerous defense mechanisms to evade both innate and adaptive immunity. As depicted in <xref rid="viruses-16-01476-f002" ref-type="fig">Figure 2</xref>, the HSV UL41 endoribonuclease vhs degrades mRNA encoding the cellular component cGAS. Simultaneously, the HSV ICP27 protein inhibits the serine&#8211;threonine kinase TBK1, which is crucial for the cell&#8217;s inflammatory response by phosphorylating the oligomerized stimulator of interferon genes (STING). This inhibition prevents the recruitment of TRAF6, thereby blocking the activation of nuclear factor-kappa B (NF-&#954;B) and suppressing the inflammatory response (<xref rid="viruses-16-01476-f002" ref-type="fig">Figure 2</xref>). Additionally, HSV ICP27 inhibits interferon regulatory factor 3 (IRF3), which can also activate NF-&#954;B [<xref rid="B28-viruses-16-01476" ref-type="bibr">28</xref>]. The HSV proteins UL42 and HSV-1 &#947;34.5 further inhibit the nuclear translocation of the p50 and p65 subunits of NF-&#954;B, thus suppressing the activation of inflammatory genes [<xref rid="B29-viruses-16-01476" ref-type="bibr">29</xref>].</p><p>Herpesviruses also hijack component proteins of the host ubiquitin machinery to subvert cellular processes and promote replication [<xref rid="B17-viruses-16-01476" ref-type="bibr">17</xref>,<xref rid="B30-viruses-16-01476" ref-type="bibr">30</xref>]. During HSV-1 infection, these events are largely driven by the E3 ubiquitin ligase ICP0, which promotes the successful onset of lytic infection and the productive reactivation of viral genomes from latency (see <xref rid="sec2dot1-viruses-16-01476" ref-type="sec">Section 2.1</xref>). It has been suggested that identifying and developing inhibitors to ICP0 could be beneficial in treating recurrent HSV-1 infections by allowing host immune defenses to block viral reactivation from latency [<xref rid="B29-viruses-16-01476" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot3-viruses-16-01476"><title>2.3. Current HSV Therapy</title><p>The synthetic acyclic guanosine analog acyclovir (ACV), discovered in the 1970s [<xref rid="B31-viruses-16-01476" ref-type="bibr">31</xref>], remains the first-line agent for the prophylaxis and treatment of HSV infections. ACV is phosphorylated by the virally encoded thymidine kinase UL23 and then further converted to acyclovir triphosphate by cellular enzymes. This form is incorporated into the HSV viral DNA, halting further chain elongation due to the absence of a 3&#8242;-hydroxyl group, thereby preventing viral replication [<xref rid="B32-viruses-16-01476" ref-type="bibr">32</xref>]. ACV is generally well tolerated, though rare adverse events can include nephrotoxicity (due to crystallization within renal tubules), neurotoxicity, disseminated intravascular coagulation, and pregnancy complications (owing to its ability to cross the placenta) [<xref rid="B33-viruses-16-01476" ref-type="bibr">33</xref>]. Other FDA-approved antiviral medications, including penciclovir, famciclovir, ganciclovir, valacyclovir, cidofovir, and foscarnet, are currently used for the treatment of herpetic skin lesions. However, the limited efficacy of these antiviral medications is a significant concern, as they typically only shorten the recovery period by 1&#8211;2 days, with some patients experiencing no benefit [<xref rid="B34-viruses-16-01476" ref-type="bibr">34</xref>]. Additionally, several natural remedies, such as lemon balm, propolis, and oral and topical zinc, have been shown to ameliorate HSV outbreaks and complications, with some demonstrating efficacy comparable to nucleoside analogs [<xref rid="B35-viruses-16-01476" ref-type="bibr">35</xref>].</p></sec></sec><sec id="sec3-viruses-16-01476"><title>3. HSV Vaccines</title><p>Although efforts to develop an HSV vaccine date back to the 1920s [<xref rid="B5-viruses-16-01476" ref-type="bibr">5</xref>], these initial attempts did not result in an effective candidate [<xref rid="B36-viruses-16-01476" ref-type="bibr">36</xref>]. In 1999, a review article emphasized that an ideal prophylactic vaccine should induce sterilizing immunity, preventing all viral entry points into the human host, including the genital tract, nasal and oropharyngeal mucosa, and the eye, to avert both primary and latent infections [<xref rid="B37-viruses-16-01476" ref-type="bibr">37</xref>].</p><p>Given that HSV-1 and HSV-2 share 80% genetic homology [<xref rid="B38-viruses-16-01476" ref-type="bibr">38</xref>], their vaccine development should be approached together, focusing on therapeutic and prophylactic strategies. Prophylactic vaccines aim to provide immunity before exposure to the virus, while therapeutic vaccines target symptom reduction in already infected individuals. However, developing prophylactic vaccines is more complex due to ethical considerations and challenges in trial recruitment, resulting in a higher prevalence of therapeutic vaccine studies. Despite many candidates showing promise in early development stages, such as animal studies, these results have often lacked replication in human trials. For example, mice, guinea pigs, and even nonhuman primates such as rhesus macaques have demonstrated poor prediction of human prophylaxis, although <italic toggle="yes">Cebus apella</italic> monkeys were recently shown to be capable of mimicking human HSV-2 infection [<xref rid="B39-viruses-16-01476" ref-type="bibr">39</xref>]. One major issue has been the lack of broad HSV antibodies and strong cell-mediated immune responses in vaccine recipients, despite high levels of specific neutralizing antibodies observed in clinical studies [<xref rid="B40-viruses-16-01476" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01476" ref-type="bibr">41</xref>].</p><p>To address these challenges, the National Institutes of Health launched the 2023&#8211;2028 NIH Strategic Plan for HSV Research to achieve the longstanding goal of the therapeutic defeat of HSV [<xref rid="B42-viruses-16-01476" ref-type="bibr">42</xref>]. Despite the difficulties, there are reasons for optimism. For example, varicella zoster virus (VZV), an alpha-herpesvirus closely related to HSV and responsible for shingles and chickenpox, is an effective live-attenuated vaccine available for prophylactic and therapeutic use [<xref rid="B43-viruses-16-01476" ref-type="bibr">43</xref>]. The successful development of the human papillomavirus vaccine further demonstrates that an intramuscularly administered vaccine can effectively combat a mucosal genital viral pathogen [<xref rid="B44-viruses-16-01476" ref-type="bibr">44</xref>]. The recent availability of full-length viral sequences for HSV-1 and HSV-2, coupled with an enhanced understanding of humoral- and cell-mediated immunity, holds promise for designing future candidate vaccines [<xref rid="B45-viruses-16-01476" ref-type="bibr">45</xref>].</p><p>Various vaccine strategies are also under investigation, with subunit vaccines in different formats (cell culture-derived, recombinant, or modified live viruses) being the most studied. More promising approaches include live-attenuated, replication-competent, and replication-defective vaccines, as well as DNA vaccines, mRNA vaccines, and inactivated vaccines. These vaccines are at different development stages and are supported by biotechnology and pharmaceutical companies, academic institutions, and government agencies [<xref rid="B46-viruses-16-01476" ref-type="bibr">46</xref>].</p></sec><sec id="sec4-viruses-16-01476"><title>4. Vaccine Types</title><p><xref rid="viruses-16-01476-t001" ref-type="table">Table 1</xref> shows all clinically relevant vaccines in articles screened from PubMed, EMBASE, Medline, and Google Scholar. These vaccines fall into the following five classes: subunit vaccines; live-attenuated replication-competent vaccines; live-attenuated replication-defective vaccines; DNA-based vaccines; and mRNA vaccines.</p><sec id="sec4dot1-viruses-16-01476"><title>4.1. Subunit Vaccines</title><p><bold>GEN-003 (Genocea)</bold>: GEN-003 (GEN-003/MM-2) is one of the best-known candidates for HSV therapeutic vaccines, containing the recombinant HSV antigens glycoprotein D (gD) and ICP4, along with a Matrix M-2 (MM) adjuvant. In preclinical studies, Skoberne et al. (2013) demonstrated GEN-003&#8242;s induction of broad-spectrum immune responses in mice and therapeutic efficacy in guinea pigs while decreasing recurrent shedding [<xref rid="B47-viruses-16-01476" ref-type="bibr">47</xref>]. In 2015, GEN-003 phase 1 and 2 trials demonstrated significantly reduced genital lesions and viral shedding in over 310 participants [<xref rid="B48-viruses-16-01476" ref-type="bibr">48</xref>]. Genital HSV-2 shedding was significantly reduced in all active vaccine groups, with a 60% reduction in the rate of genital lesions and elevated neutralizing antibody titers. Despite such promising results, Genocea ceased spending on GEN-003, shifting its focus to neoantigen cancer vaccines in 2017 [<xref rid="B49-viruses-16-01476" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01476" ref-type="bibr">50</xref>].</p><p><bold>VCL-HB01 (Vical)</bold>: Another therapeutic vaccine candidate that was recently abandoned was VCL-HB01, a DNA plasmid vaccine consisting of polynucleotides encoding codon-optimized gD2 and VP11/12 in combination with Vaxfectin, a lipid-based compound designed to enhance protein expression [<xref rid="B51-viruses-16-01476" ref-type="bibr">51</xref>]. A phase 2 study conducted on 261 healthy HSV-2-seropositive adults with a self-reported history of at least 4 to 9 yearly recurrences did not meet its primary endpoint of reducing lesion recurrence rates despite the absence of serious adverse effects. Hence, VCL-HB01 represents another vaccine candidate targeting HSV glycoproteins that failed to progress after unsatisfactory phase 2 results [<xref rid="B52-viruses-16-01476" ref-type="bibr">52</xref>].</p><p><bold>HerpV (Agenus)</bold>: The HerpV therapeutic glycoprotein subunit vaccine is another HSV subunit vaccine that failed to progress past phase 2. HerpV (formerly called AG-707) consists of 32 HSV-2 peptides derived from 22 HSV-2 proteins that are non-covalently complexed to a heat shock protein 70 (HSP70) chaperone and formulated with a QS-21 saponin adjuvant [<xref rid="B53-viruses-16-01476" ref-type="bibr">53</xref>]. Peptides for the vaccine, which include proteins spanning all classes of herpes proteins, were selected based on algorithms predicting human leukocyte antigen binding, synthesis feasibility, and proteasomal processing. Preliminary results from a phase 2 study of HerpV showed a 15% decrease in viral shedding, which persisted up to 6 months after the initial vaccine series [<xref rid="B54-viruses-16-01476" ref-type="bibr">54</xref>].</p><p><bold>Simplirix (GlaxoSmithKline)</bold>: This truncated glycoprotein D2 (gD2) vaccine candidate was tested in the phase 3 Herpevac Trial for Women [<xref rid="B55-viruses-16-01476" ref-type="bibr">55</xref>]. Subjects were vaccinated with either the investigational vaccine (consisting of 20 &#956;g of glycoprotein D2 from HSV-2 strain G in alum and 3-O-deacylated monophosphoryl lipid A as an adjuvant) or a control hepatitis A vaccine. Three doses of the vaccine were 58% protective against culture-positive HSV-1 genital disease but not protective against HSV-2 infection or disease [<xref rid="B55-viruses-16-01476" ref-type="bibr">55</xref>]. Ultimately, it was concluded that the vaccine was unsuccessful in preventing HSV-2 infection or disease, as some women who became infected during the trial experienced recurrent disease [<xref rid="B55-viruses-16-01476" ref-type="bibr">55</xref>].</p></sec><sec id="sec4dot2-viruses-16-01476"><title>4.2. Live-Attenuated Replication-Competent Vaccines</title><p><bold>HF10</bold>: With decades of failure in subunit vaccines, recent focus has shifted to other vaccine candidates. Of these, the first to start development was HF10, a live-attenuated replication-competent HSV-1 naturally mutated vaccine (i.e., not engineered) for the genes <italic toggle="yes">UL43</italic>, <italic toggle="yes">UL49.5</italic>, <italic toggle="yes">UL55</italic>, and <italic toggle="yes">UL56</italic>, and latency-associated transcripts [<xref rid="B56-viruses-16-01476" ref-type="bibr">56</xref>]. Immunization with HF10 protected mice against clinical symptoms elicited by HSV-2 inhibited HSV-2 replication at the site of virus introduction, reduced local inflammation, blocked neuroinvasion, and increased survival [<xref rid="B57-viruses-16-01476" ref-type="bibr">57</xref>]. The protective effect of HF10 was also related to the induction of cellular immunity, mediated mainly by Th1 CD4+ T cells [<xref rid="B57-viruses-16-01476" ref-type="bibr">57</xref>].</p><p><bold>0&#916;NLS (RVx201) (from Rational Vaccines)</bold>: 0&#916;NLS (RVx201) is modified to be interferon sensitive and is thus unable to inhibit intracellular antiviral responses [<xref rid="B58-viruses-16-01476" ref-type="bibr">58</xref>]. In preclinical studies, 0&#916;NLS inhibited vaginal shedding in guinea pigs and could not establish latency in dorsal root ganglia, leading to the suppression of HSV reactivation [<xref rid="B58-viruses-16-01476" ref-type="bibr">58</xref>]. The vaccine also conferred protective immunity to ocular HSV-1 challenge (pathology-free corneas) with reduced infection of the nervous system [<xref rid="B59-viruses-16-01476" ref-type="bibr">59</xref>]. As a live vaccine, the 0&#916;NLS vaccine is avirulent yet replication-competent and can elicit immunogenicity without producing clinical disease. This vaccine reactivates subclinically, eliciting immunogenicity against a wild-type virus, thus allowing the host to acquire protective immunity [<xref rid="B60-viruses-16-01476" ref-type="bibr">60</xref>]. Nonclinical studies demonstrated that HSV-2 0&#916;NLS is replication-competent, interferon-sensitive, and avirulent in immunocompetent mice, achieving an optimal balance between attenuation versus capacity to stimulate a protective immune response [<xref rid="B61-viruses-16-01476" ref-type="bibr">61</xref>]. Such balance allows for better protection of its subjects from HSV compared with other vaccines, such as the leading candidate at that time (2011), the gD2 Herpevac trial vaccine [<xref rid="B62-viruses-16-01476" ref-type="bibr">62</xref>]. Although one of the safety trials was controversial [<xref rid="B63-viruses-16-01476" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01476" ref-type="bibr">64</xref>], in 2021, the vaccine received an Innovation Passport from the UK&#8217;s MHRA (Medicine and Healthcare Products Regulatory Agency)-led Innovative Licensing and Access Pathway (ILAP) [<xref rid="B65-viruses-16-01476" ref-type="bibr">65</xref>]. Rational Vaccines, Inc. (Woburn, MA) also recently received a grant from the National Institutes for Allergy and Infectious Diseases for further vaccine studies [<xref rid="B66-viruses-16-01476" ref-type="bibr">66</xref>].</p><p><bold>VC2 (Rational Vaccines)</bold>: VC2 is a live-attenuated HSV-1 vaccine engineered to be incapable of entering neuronal axons. Such attempts to minimize side effects via engineering have been labeled rational [<xref rid="B67-viruses-16-01476" ref-type="bibr">67</xref>]. VC2, which possesses deletions of gK aa31-68 and UL20 aa4-22, successfully protected against ocular immunopathogenesis in mice while preventing viral entry to neurons [<xref rid="B68-viruses-16-01476" ref-type="bibr">68</xref>]. In addition, intramuscular administration to guinea pigs produced a transcriptional profile of Th17 and regulatory Tr1 responses [<xref rid="B69-viruses-16-01476" ref-type="bibr">69</xref>].</p></sec><sec id="sec4dot3-viruses-16-01476"><title>4.3. Replication-Defective Vaccines</title><p><bold>HSV529 (Sanofi Pasteur)</bold>: The HSV529 vaccine is a live HSV-1 virus depleted of UL5 and UL29 [<xref rid="B70-viruses-16-01476" ref-type="bibr">70</xref>,<xref rid="B71-viruses-16-01476" ref-type="bibr">71</xref>]. It was shown to elicit both humoral- and cell-mediated immunity, serum-neutralizing antibody titers, serum and vaginal antibodies to HSV-2 glycoprotein D, HSV2-specific antibody-dependent cellular cytotoxicity, and CD4+ and CD8+ T cell responses. Serum-neutralizing antibody titers significantly increased after three doses of HSV529, and this increase persisted for up to 6 months (<italic toggle="yes">p</italic> &lt; 0.001), as did increased serum and vaginal antibodies to HSV-2 glycoprotein D (gD). In addition, the vaccine significantly induced HSV-2-specific antibody-dependent cellular cytotoxicity (<italic toggle="yes">p</italic> &lt; 0.001). CD4+ T-cell responses were detected in 46%, 27%, and 36% of subjects in groups 1, 2, and 3, respectively. Concurrently, CD8+ T-cell responses were detected in 8%, 18%, and 14% of subjects in groups 1, 2, and 3, respectively [<xref rid="B71-viruses-16-01476" ref-type="bibr">71</xref>].</p><p>89% of vaccine recipients experienced a mild-to-moderate injection site reaction versus 47% of placebo recipients. A total of 64% of vaccine recipients experienced systemic reactions versus 53% of placebo recipients. Two documented serious adverse events in two participants were concluded to be unrelated to HSV529 administration.</p></sec><sec id="sec4dot4-viruses-16-01476"><title>4.4. DNA Vaccines</title><p><bold>COR-1</bold>: Cor-1 is a DNA vaccine consisting of two plasmids. One (codon optimized) codes for the HSV-2 envelope glycoprotein D (gD2), and the second has a truncated gD2 fused to ubiquitin [<xref rid="B72-viruses-16-01476" ref-type="bibr">72</xref>]. In a preclinical model, Cor-1 induced a balanced adaptive humoral- and cell-mediated immune response in mice [<xref rid="B73-viruses-16-01476" ref-type="bibr">73</xref>], while a phase 1 dose-escalating study showed safety and tolerability in 20 subjects.</p><p><bold>SL-V20 (SL VAXiGEN)</bold>: SL-V20, a plasmid DNA vaccine against HSV2 glycoproteins gC, gD, and the UL39 ribonucleotide reductase, was 100% effective against mouse lethal challenge while also completely preventing vaginal infection. SL-V20 effects were T-cell-mediated, with B cells being dispensable to responses [<xref rid="B74-viruses-16-01476" ref-type="bibr">74</xref>]. The current status of this vaccine is unclear.</p></sec><sec id="sec4dot5-viruses-16-01476"><title>4.5. mRNA Vaccines</title><p><bold>mRNA-1608 (Moderna)</bold>: The COVID-19 pandemic ushered in the successful development of mRNA vaccines, which are now under study for multiple diseases, including Alzheimer&#8217;s disease and cancer. For HSV-2, Moderna, in collaboration with the University of Pennsylvania, has developed mRNA-1608-P101, a trivalent vaccine against HSV-2 gC2, gD2, and gE2 that is currently in a phase 1/2 trial for 365 patients aged 18 to 55 years (Clinicaltrials.gov ID <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06033261">NCT06033261</ext-link>). The trial&#8217;s duration is from September 2023 to June 2025. In preclinical studies, mRNA-1608 provided mice with 100% protection against lethal challenge [<xref rid="B75-viruses-16-01476" ref-type="bibr">75</xref>] while also preventing dorsal root ganglion infection and inducing high titers of neutralizing antibodies and durable responses of CD4+ T follicular helper and memory B cells [<xref rid="B76-viruses-16-01476" ref-type="bibr">76</xref>,<xref rid="B77-viruses-16-01476" ref-type="bibr">77</xref>]. In rhesus macaques, the trivalent mRNA-1608 vaccine-induced neutralizing antibodies blocking gC2 and gE2 immune evasion, stimulated CD4 T cell responses, and elicited 100% protection in the vaginal challenge [<xref rid="B78-viruses-16-01476" ref-type="bibr">78</xref>]. Comparison of the mRNA/nanoparticle formulation to baculovirus proteins with CpG/alum revealed day 2 and 4 vaginal cultures to be negative in 23 of 30 (73%) mice in the baculovirus group compared with 63 of 64 (98%) in the mRNA group [<xref rid="B77-viruses-16-01476" ref-type="bibr">77</xref>]. In guinea pigs, 5 of 10 (50%) animals in the trivalent subunit protein group had vaginal shedding of HSV-2 DNA in 19 of 210 (9%) days, compared with 2 of 10 (20%) animals in the mRNA group that shed HSV-2 DNA in 5 of 210 (2%) days (<italic toggle="yes">p</italic> = 0.0052).</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-16-01476"><title>5. Conclusions and Future Directions</title><p>Humankind has contended with HSV viruses for millennia. As of 2024, significant strides have been made toward overcoming a virus that has persistently challenged our immune system throughout time. Our review identified 12 relevant vaccines, highlighting both progress and setbacks. Despite promising expectations, Genocea ceased the development of GEN-003 in 2017 to focus on neoantigen cancer vaccines. Similarly, HerpV, a subunit vaccine from Agenus, did not progress beyond favorable phase 1 results. </p><p>On the other hand, there are vaccine candidates actively undergoing clinical trials, which include 0&#916;NLS (a live-attenuated vaccine from Rational Vaccines), mRNA-1608 (a mRNA vaccine from Moderna), and COR-1 (a DNA-based vaccine from Anteris Technologies). Several vaccines have shown promising findings in preclinical studies as well. For example, the live vaccine 0&#916;NLS demonstrated superior efficacy compared to gD2 vaccines (such as the Herpevac trial vaccine) in protecting guinea pigs from lethal challenges. Moderna&#8217;s mRNA vaccine has recently shown an 85% to 100% reduction in animal genital disease. Ongoing and future clinical trials will be necessary to evaluate the full efficacy and safety of HF10, VC2, and HSV 529 in humans.</p><p>Compared with subunit vaccines, other forms of vaccines, such as live-attenuated vaccines, hold promise for HSV due to the virus&#8217; complex structures and ability to target multiple mechanisms of action, particularly when the virus is latent in neuronal cells. While these vaccines still need to be carefully evaluated in future clinical trials, the potential benefits they offer make them a promising avenue for further research and development.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Two authors, J.Y.C. and C.B., conducted the literature search and decided which articles would be included. H.S.O. provided critical insight for the paper. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>Author J.Y.C. was employed by the company Ascendant Biotech Inc., while author C.B. was self-employed. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01476"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szpara</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Gatherer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ochoa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greenbaum</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dolan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bowden</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Enquist</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Legendre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Davison</surname><given-names>A.J.</given-names></name></person-group><article-title>Evolution and diversity in human herpes simplex virus genomes</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1209</fpage><lpage>1227</lpage><pub-id pub-id-type="pmid">24227835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01987-13</pub-id><pub-id pub-id-type="pmcid">PMC3911644</pub-id></element-citation></ref><ref id="B2-viruses-16-01476"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Mathew</surname><given-names>J.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Sapra</surname><given-names>A.</given-names></name></person-group><article-title>Herpes simplex type 2</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2023</year></element-citation></ref><ref id="B3-viruses-16-01476"><label>3.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Saleh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yarrarapu</surname><given-names>S.N.S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name></person-group><article-title>Herpes simplex type 1</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2023</year><pub-id pub-id-type="pmid">29489260</pub-id></element-citation></ref><ref id="B4-viruses-16-01476"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>S.W.H.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Chaiyakunapruk</surname><given-names>N.</given-names></name></person-group><article-title>Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: A systematic review</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e049618</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmjopen-2021-049618</pub-id><pub-id pub-id-type="pmcid">PMC8728455</pub-id><pub-id pub-id-type="pmid">34983754</pub-id></element-citation></ref><ref id="B5-viruses-16-01476"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zinsser</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>F.F.</given-names></name></person-group><article-title>Immunological studies with herpes virus with a consideration of the herpes-encephalitis problem</article-title><source>J. Exp. Med.</source><year>1926</year><volume>44</volume><fpage>21</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">19869171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.44.1.21</pub-id><pub-id pub-id-type="pmcid">PMC2180264</pub-id></element-citation></ref><ref id="B6-viruses-16-01476"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freeman</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>White</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>R.</given-names></name><name name-style="western"><surname>Orroth</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Buv&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Glynn</surname><given-names>J.R.</given-names></name></person-group><article-title>Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>940</fpage><lpage>946</lpage><pub-id pub-id-type="pmid">19071187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.11.074</pub-id><pub-id pub-id-type="pmcid">PMC2686080</pub-id></element-citation></ref><ref id="B7-viruses-16-01476"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bradu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jagdeo</surname><given-names>J.</given-names></name></person-group><article-title>The association between herpes simplex virus and Alzheimer&#8217;s disease: A systematic review</article-title><source>J. Drugs Dermatol.</source><year>2023</year><volume>22</volume><fpage>1046</fpage><lpage>1052</lpage><pub-id pub-id-type="pmid">37801540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.36849/JDD.6785</pub-id></element-citation></ref><ref id="B8-viruses-16-01476"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Protto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marcocci</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Miteva</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Piacentini</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li Puma</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Grassi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Palamara</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>De Chiara</surname><given-names>G.</given-names></name></person-group><article-title>Role of HSV-1 in Alzheimer&#8217;s disease pathogenesis: A challenge for novel preventive/therapeutic strategies</article-title><source>Curr. Opin. Pharmacol.</source><year>2022</year><volume>63</volume><fpage>102200</fpage><pub-id pub-id-type="pmid">35276497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2022.102200</pub-id></element-citation></ref><ref id="B9-viruses-16-01476"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Deal</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Giersing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bolan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Timms</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gray-Owen</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Jerse</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.E.</given-names></name><etal/></person-group><article-title>The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2939</fpage><lpage>2947</lpage><pub-id pub-id-type="pmid">27105564</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.03.111</pub-id><pub-id pub-id-type="pmcid">PMC6759054</pub-id></element-citation></ref><ref id="B10-viruses-16-01476"><label>10.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Knipe</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Heldwein</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Sodroski</surname><given-names>C.N.</given-names></name></person-group><source>Field&#8217;s Virology: DNA Viruses</source><comment>Herpes Simplex Viruses: Mechanisms of Lytic and Latent Infection; Field&#8217;s Virology</comment><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Philadelphia, PA, USA</publisher-loc><year>2021</year><fpage>235</fpage><lpage>296</lpage></element-citation></ref><ref id="B11-viruses-16-01476"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>J.C.</given-names></name></person-group><article-title>High G+C Content of herpes simplex virus DNA: Proposed role in protection against retrotransposon insertion</article-title><source>Open Biochem. J.</source><year>2007</year><volume>1</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">19543363</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1874091X00701010033</pub-id><pub-id pub-id-type="pmcid">PMC2606590</pub-id></element-citation></ref><ref id="B12-viruses-16-01476"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spencer</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Dahmus</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>S.A.</given-names></name></person-group><article-title>Repression of host RNA polymerase II transcription by herpes simplex virus type 1</article-title><source>J. Virol.</source><year>1997</year><volume>71</volume><fpage>2031</fpage><lpage>2040</lpage><pub-id pub-id-type="pmid">9032335</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.71.3.2031-2040.1997</pub-id><pub-id pub-id-type="pmcid">PMC191289</pub-id></element-citation></ref><ref id="B13-viruses-16-01476"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Connolly</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Jardetzky</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Longnecker</surname><given-names>R.</given-names></name></person-group><article-title>The structural basis of herpesvirus entry</article-title><source>Nat. Rev. Microbiol.</source><year>2021</year><volume>2</volume><fpage>110</fpage><lpage>121</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-020-00448-w</pub-id><pub-id pub-id-type="pmcid">PMC8579738</pub-id><pub-id pub-id-type="pmid">33087881</pub-id></element-citation></ref><ref id="B14-viruses-16-01476"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Boname</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Minson</surname><given-names>T.</given-names></name></person-group><article-title>Assembly and organization of glycoproteins B, C, D, and H in herpes simplex virus type 1 particles lacking individual glycoproteins: No evidence for the formation of a complex of these molecules</article-title><source>J. Virol.</source><year>2001</year><volume>75</volume><fpage>710</fpage><lpage>716</lpage><pub-id pub-id-type="pmid">11134284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.75.2.710-716.2001</pub-id><pub-id pub-id-type="pmcid">PMC113967</pub-id></element-citation></ref><ref id="B15-viruses-16-01476"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Horton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Durr</surname><given-names>E.</given-names></name><name name-style="western"><surname>Heidecker</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Freed</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fridman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name></person-group><article-title>Evaluation of HSV-2 gE Binding to IgG-Fc and application for vaccine development</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>184</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10020184</pub-id><pub-id pub-id-type="pmid">35214644</pub-id><pub-id pub-id-type="pmcid">PMC8879737</pub-id></element-citation></ref><ref id="B16-viruses-16-01476"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanders</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Comar</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Srinivas</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Lalli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Salnikov</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lengyel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Southern</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>S.A.</given-names></name></person-group><article-title>Herpes simplex virus-1 ICP27 nuclear export signal mutants exhibit cell type-dependent deficits in replication and ICP4 expression</article-title><source>J. Virol.</source><year>2023</year><volume>97</volume><fpage>e0195722</fpage><pub-id pub-id-type="pmid">37310267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.01957-22</pub-id><pub-id pub-id-type="pmcid">PMC10373558</pub-id></element-citation></ref><ref id="B17-viruses-16-01476"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Dybas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weitzman</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Boutell</surname><given-names>C.</given-names></name></person-group><article-title>The HSV-1 ubiquitin ligase ICP0: Modifying the cellular proteome to promote infection</article-title><source>Virus Res.</source><year>2020</year><volume>285</volume><fpage>198015</fpage><pub-id pub-id-type="pmid">32416261</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2020.198015</pub-id><pub-id pub-id-type="pmcid">PMC7303953</pub-id></element-citation></ref><ref id="B18-viruses-16-01476"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mossman</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Saffran</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Smiley</surname><given-names>J.R.</given-names></name></person-group><article-title>Herpes simplex virus ICP0 mutants are hypersensitive to interferon</article-title><source>J. Virol.</source><year>2000</year><volume>74</volume><fpage>2052</fpage><lpage>2056</lpage><pub-id pub-id-type="pmid">10644380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/jvi.74.4.2052-2056.2000</pub-id><pub-id pub-id-type="pmcid">PMC111685</pub-id></element-citation></ref><ref id="B19-viruses-16-01476"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Diao</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.</given-names></name></person-group><article-title>ICP4-induced miR-101 attenuates HSV-1 replication</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><elocation-id>23205</elocation-id><pub-id pub-id-type="pmid">26984403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep23205</pub-id><pub-id pub-id-type="pmcid">PMC4794718</pub-id></element-citation></ref><ref id="B20-viruses-16-01476"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tunnicliffe</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Lockhart-Cairns</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mould</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Jowitt</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Sito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Baldock</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sandri-Goldin</surname><given-names>R.M.</given-names></name></person-group><article-title>The herpes viral transcription factor ICP4 forms a novel DNA recognition complex</article-title><source>Nucleic Acids Res.</source><year>2017</year><volume>45</volume><fpage>8064</fpage><lpage>8078</lpage><pub-id pub-id-type="pmid">28505309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx419</pub-id><pub-id pub-id-type="pmcid">PMC5737704</pub-id></element-citation></ref><ref id="B21-viruses-16-01476"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Engel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>L.</given-names></name></person-group><article-title>The HSV-1 ICP4 transcriptional auto-repression circuit functions as a transcriptional &#8220;accelerator&#8221; circuit</article-title><source>Front. Cell Infect. Microbiol.</source><year>2020</year><volume>10</volume><elocation-id>265</elocation-id><pub-id pub-id-type="pmid">32670890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fcimb.2020.00265</pub-id><pub-id pub-id-type="pmcid">PMC7326776</pub-id></element-citation></ref><ref id="B22-viruses-16-01476"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostafa</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Davido</surname><given-names>D.J.</given-names></name></person-group><article-title>Herpes simplex virus 1 ICP22 but not US 1.5 is required for efficient acute replication in mice and VICE domain formation</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>13510</fpage><lpage>13519</lpage><pub-id pub-id-type="pmid">24089574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02424-13</pub-id><pub-id pub-id-type="pmcid">PMC3838291</pub-id></element-citation></ref><ref id="B23-viruses-16-01476"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Packard</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Dembowski</surname><given-names>J.A.</given-names></name></person-group><article-title>HSV-1 DNA replication-coordinated regulation by viral and cellular factors</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>2015</fpage><pub-id pub-id-type="pmid">34696446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13102015</pub-id><pub-id pub-id-type="pmcid">PMC8539067</pub-id></element-citation></ref><ref id="B24-viruses-16-01476"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Che</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name></person-group><article-title>HSV-1 tegument protein and the development of its genome editing technology</article-title><source>Virol. J.</source><year>2016</year><volume>13</volume><fpage>108</fpage><pub-id pub-id-type="pmid">27343062</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12985-016-0563-x</pub-id><pub-id pub-id-type="pmcid">PMC4919851</pub-id></element-citation></ref><ref id="B25-viruses-16-01476"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watson</surname><given-names>Z.L.</given-names></name><name name-style="western"><surname>Washington</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Phelan</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lewin</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tuli</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Schultz</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>D.C.</given-names></name></person-group><article-title>In vivo knockdown of the herpes simplex virus 1 latency-associated transcript reduces reactivation from latency</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e00812-18</fpage><pub-id pub-id-type="pmid">29875240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00812-18</pub-id><pub-id pub-id-type="pmcid">PMC6069208</pub-id></element-citation></ref><ref id="B26-viruses-16-01476"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Majewska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mlynarczyk-Bonikowska</surname><given-names>B.</given-names></name></person-group><article-title>40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>3431</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23073431</pub-id><pub-id pub-id-type="pmid">35408788</pub-id><pub-id pub-id-type="pmcid">PMC8998721</pub-id></element-citation></ref><ref id="B27-viruses-16-01476"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Mohr</surname><given-names>I.</given-names></name></person-group><article-title>A cultured affair: HSV latency and reactivation in neurons</article-title><source>Trends Microbiol.</source><year>2012</year><volume>20</volume><fpage>604</fpage><lpage>611</lpage><pub-id pub-id-type="pmid">22963857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tim.2012.08.005</pub-id><pub-id pub-id-type="pmcid">PMC3989139</pub-id></element-citation></ref><ref id="B28-viruses-16-01476"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krawczyk</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kangas</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name></person-group><article-title>HSV Replication: Triggering and repressing STING functionality</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>226</elocation-id><pub-id pub-id-type="doi">10.3390/v15010226</pub-id><pub-id pub-id-type="pmid">36680267</pub-id><pub-id pub-id-type="pmcid">PMC9864509</pub-id></element-citation></ref><ref id="B29-viruses-16-01476"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ike</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Onu</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Ononugbo</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Reward</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Muo</surname><given-names>S.O.</given-names></name></person-group><article-title>Immune response to herpes simplex virus infection and vaccine development</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>302</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8020302</pub-id><pub-id pub-id-type="pmid">32545507</pub-id><pub-id pub-id-type="pmcid">PMC7350219</pub-id></element-citation></ref><ref id="B30-viruses-16-01476"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boutell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Everett</surname><given-names>R.D.</given-names></name></person-group><article-title>Regulation of alphaherpesvirus infections by the ICP0 family of proteins</article-title><source>J. Gen. Virol.</source><year>2013</year><volume>94</volume><issue-part>Pt 3</issue-part><fpage>465</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">23239572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/vir.0.048900-0</pub-id></element-citation></ref><ref id="B31-viruses-16-01476"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>King</surname><given-names>D.H.</given-names></name></person-group><article-title>History, pharmacokinetics, and pharmacology of acyclovir</article-title><source>J. Am. Acad. Dermatol.</source><year>1988</year><volume>18</volume><issue-part>Pt 2</issue-part><fpage>176</fpage><lpage>179</lpage><pub-id pub-id-type="pmid">2828440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0190-9622(88)70022-5</pub-id></element-citation></ref><ref id="B32-viruses-16-01476"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gerriets</surname><given-names>V.</given-names></name></person-group><article-title>Acyclovir</article-title><source>StatPearls</source><publisher-name>StatPearls Publishing</publisher-name><publisher-loc>Treasure Island, FL, USA</publisher-loc><year>2022</year></element-citation></ref><ref id="B33-viruses-16-01476"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wei</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y.-L.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.-H.</given-names></name><name name-style="western"><surname>He</surname><given-names>Q.-G.</given-names></name></person-group><article-title>Critical review of synthesis, toxicology and detection of acyclovir</article-title><source>Molecules</source><year>2021</year><volume>26</volume><elocation-id>6566</elocation-id><pub-id pub-id-type="doi">10.3390/molecules26216566</pub-id><pub-id pub-id-type="pmid">34770975</pub-id><pub-id pub-id-type="pmcid">PMC8587948</pub-id></element-citation></ref><ref id="B34-viruses-16-01476"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poole</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>James</surname><given-names>S.H.</given-names></name></person-group><article-title>Antiviral therapies for herpesviruses: Current agents and new directions</article-title><source>Clin. Ther.</source><year>2018</year><volume>40</volume><fpage>1282</fpage><lpage>1298</lpage><pub-id pub-id-type="pmid">30104016</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clinthera.2018.07.006</pub-id><pub-id pub-id-type="pmcid">PMC7728158</pub-id></element-citation></ref><ref id="B35-viruses-16-01476"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Balch</surname><given-names>C.</given-names></name><name name-style="western"><surname>Puccio</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.S.</given-names></name></person-group><article-title>A narrative review of alternative symptomatic treatments for herpes simplex virus</article-title><source>Viruses</source><year>2023</year><volume>5</volume><fpage>1314</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v15061314</pub-id><pub-id pub-id-type="pmcid">PMC10301284</pub-id><pub-id pub-id-type="pmid">37376614</pub-id></element-citation></ref><ref id="B36-viruses-16-01476"><label>36.</label><element-citation publication-type="book"><person-group person-group-type="editor"><name name-style="western"><surname>Arvin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campadelli-Fiume</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mocarski</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Roizman</surname><given-names>B.</given-names></name><name name-style="western"><surname>Whitley</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yamanishi</surname><given-names>K.</given-names></name></person-group><source>Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis</source><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc><year>2007</year><pub-id pub-id-type="pmid">21348071</pub-id></element-citation></ref><ref id="B37-viruses-16-01476"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Stanberry</surname><given-names>L.R.</given-names></name></person-group><article-title>Herpes simplex virus vaccines</article-title><source>Vaccine</source><year>1999</year><volume>17</volume><fpage>1681</fpage><lpage>1689</lpage><pub-id pub-id-type="pmid">10194823</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(98)00434-4</pub-id></element-citation></ref><ref id="B38-viruses-16-01476"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Norberg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kasubi</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Haarr</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bergstrom</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liljeqvist</surname><given-names>J.A.</given-names></name></person-group><article-title>Divergence and recombination of clinical herpes simplex virus type 2 isolates</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>13158</fpage><lpage>13167</lpage><pub-id pub-id-type="pmid">17881457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01310-07</pub-id><pub-id pub-id-type="pmcid">PMC2169075</pub-id></element-citation></ref><ref id="B39-viruses-16-01476"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dowdell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Herbert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>I.N.</given-names></name><name name-style="western"><surname>Koelle</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.I.</given-names></name></person-group><article-title>A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion</article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1012477</elocation-id><pub-id pub-id-type="pmid">39226323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1012477</pub-id><pub-id pub-id-type="pmcid">PMC11371218</pub-id></element-citation></ref><ref id="B40-viruses-16-01476"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halford</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Geltz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Hasenkrug</surname><given-names>K.J.</given-names></name></person-group><article-title>Antibodies Are Required for Complete Vaccine-Induced Protection against Herpes Simplex Virus 2</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0145228</elocation-id><pub-id pub-id-type="pmid">26670699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0145228</pub-id><pub-id pub-id-type="pmcid">PMC4682860</pub-id></element-citation></ref><ref id="B41-viruses-16-01476"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halford</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Geltz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gershburg</surname><given-names>E.</given-names></name></person-group><article-title>Pan-HSV-2 IgG antibody in vaccinated mice and guinea pigs correlates with protection against herpes simplex virus 2</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e65523</elocation-id><pub-id pub-id-type="pmid">23755244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0065523</pub-id><pub-id pub-id-type="pmcid">PMC3675040</pub-id></element-citation></ref><ref id="B42-viruses-16-01476"><label>42.</label><element-citation publication-type="gov"><article-title>2023-2028 Strategic Plan for HERPES SIMPLEX VIRUS Research. National Institutes of Health</article-title><month>September</month><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.niaid.nih.gov/sites/default/files/nih-herpes-simplex-strategic-plan-2023.pdf" ext-link-type="uri">https://www.niaid.nih.gov/sites/default/files/nih-herpes-simplex-strategic-plan-2023.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B43-viruses-16-01476"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oxman</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Levin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Schmader</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Straus</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Gelb</surname><given-names>L.D.</given-names></name><name name-style="western"><surname>Arbeit</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Simberkoff</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Gershon</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>L.E.</given-names></name><etal/></person-group><article-title>A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults</article-title><source>N. Engl. J. Med.</source><year>2005</year><volume>352</volume><fpage>2271</fpage><lpage>2284</lpage><pub-id pub-id-type="pmid">15930418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa051016</pub-id></element-citation></ref><ref id="B44-viruses-16-01476"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garland</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hernandez-Avila</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>G.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Leodolter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Steben</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases</article-title><source>N. Engl. J. Med.</source><year>2007</year><volume>356</volume><fpage>1928</fpage><lpage>1943</lpage><pub-id pub-id-type="pmid">17494926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa061760</pub-id></element-citation></ref><ref id="B45-viruses-16-01476"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Newman</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lamers</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ray</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Colgrove</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Diaz</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Saif</surname><given-names>S.</given-names></name><name name-style="western"><surname>Young</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Genome sequencing and analysis of geographically diverse clinical isolates of herpes simplex virus 2</article-title><source>J. Virol.</source><year>2015</year><volume>89</volume><fpage>8219</fpage><lpage>8232</lpage><pub-id pub-id-type="pmid">26018166</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01303-15</pub-id><pub-id pub-id-type="pmcid">PMC4524243</pub-id></element-citation></ref><ref id="B46-viruses-16-01476"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>A.</given-names></name></person-group><article-title>Status of vaccine research and development of vaccines for herpes simplex virus</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2948</fpage><lpage>2952</lpage><pub-id pub-id-type="pmid">26973067</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.12.076</pub-id></element-citation></ref><ref id="B47-viruses-16-01476"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Skoberne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cardin</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kazimirova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>V.</given-names></name><name name-style="western"><surname>Garvie</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lundberg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><etal/></person-group><article-title>An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in guinea pigs</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>3930</fpage><lpage>3942</lpage><pub-id pub-id-type="pmid">23365421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02745-12</pub-id><pub-id pub-id-type="pmcid">PMC3624190</pub-id></element-citation></ref><ref id="B48-viruses-16-01476"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Wagoner</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fife</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leone</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Warren</surname><given-names>T.</given-names></name><name name-style="western"><surname>Panther</surname><given-names>L.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Beigi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kriesel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tyring</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Effects of different doses of GEN-003, a therapeutic vaccine for genital herpes simplex virus-2, on viral shedding and lesions: Results of a randomized placebo-controlled trial</article-title><source>J. Infect. Dis.</source><year>2018</year><volume>218</volume><fpage>1890</fpage><lpage>1899</lpage><pub-id pub-id-type="pmid">29982727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiy415</pub-id><pub-id pub-id-type="pmcid">PMC7191615</pub-id></element-citation></ref><ref id="B49-viruses-16-01476"><label>49.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Bloom</surname><given-names>J.</given-names></name></person-group><article-title>&#8220;Bombs Away: Genocea&#8217;s Herpes Vaccine Goes Down in Flames&#8221;. Bombs Away: Genocea&#8217;s Herpes Vaccine Goes Down in Flames|American Council on Science and Health</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.acsh.org/news/2017/09/25/bombs-away-genoceas-herpes-vaccine-goes-down-flames-11874" ext-link-type="uri">https://www.acsh.org/news/2017/09/25/bombs-away-genoceas-herpes-vaccine-goes-down-flames-11874</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B50-viruses-16-01476"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Flechtner</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>McNeil</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Heineman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oliphant</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tasker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wald</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hetherington</surname><given-names>S.</given-names></name><collab>Genocea Study Group</collab></person-group><article-title>Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3443</fpage><lpage>3450</lpage><pub-id pub-id-type="pmid">31103365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.05.009</pub-id></element-citation></ref><ref id="B51-viruses-16-01476"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Dutton</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kinrade</surname><given-names>S.</given-names></name><name name-style="western"><surname>Druce</surname><given-names>J.</given-names></name><name name-style="western"><surname>Finlayson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Laing</surname><given-names>J.K.</given-names></name><etal/></person-group><article-title>Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0226320</elocation-id><pub-id pub-id-type="pmid">31846475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0226320</pub-id><pub-id pub-id-type="pmcid">PMC6917347</pub-id></element-citation></ref><ref id="B52-viruses-16-01476"><label>52.</label><element-citation publication-type="webpage"><article-title>Vical Incorporated. Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint. GlobeNewswire</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.clinicaltrialsarena.com/company-news/vical-reports-negative-results-phase-ll-trial-hsv-2-vaccine/" ext-link-type="uri">https://www.clinicaltrialsarena.com/company-news/vical-reports-negative-results-phase-ll-trial-hsv-2-vaccine/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B53-viruses-16-01476"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Musselli</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pappas</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leclair</surname><given-names>K.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chicz</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Truneh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levey</surname><given-names>D.L.</given-names></name></person-group><article-title>A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>8530</fpage><lpage>8541</lpage><pub-id pub-id-type="pmid">21767588</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.07.011</pub-id></element-citation></ref><ref id="B54-viruses-16-01476"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Flechtner</surname><given-names>J.B.</given-names></name></person-group><article-title>Evolution of rational vaccine designs for genital herpes immunotherapy</article-title><source>Curr. Opin. Virol.</source><year>2016</year><volume>17</volume><fpage>80</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">26896782</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coviro.2016.01.021</pub-id></element-citation></ref><ref id="B55-viruses-16-01476"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Minaya</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Korom</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Belshe</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>L.A.</given-names></name></person-group><article-title>The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0176687</elocation-id><pub-id pub-id-type="pmid">28448558</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0176687</pub-id><pub-id pub-id-type="pmcid">PMC5407825</pub-id></element-citation></ref><ref id="B56-viruses-16-01476"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mori</surname><given-names>I.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goshima</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koide</surname><given-names>N.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yokochi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>Y.</given-names></name></person-group><article-title>HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2</article-title><source>Microbes Infect.</source><year>2005</year><volume>7</volume><fpage>1492</fpage><lpage>1500</lpage><pub-id pub-id-type="pmid">16054416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2005.05.007</pub-id></element-citation></ref><ref id="B57-viruses-16-01476"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goshima</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kamakura</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mutoh</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Iwata</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nishiyama</surname><given-names>Y.</given-names></name></person-group><article-title>Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2</article-title><source>Front. Microbiol.</source><year>2012</year><volume>3</volume><elocation-id>158</elocation-id><pub-id pub-id-type="pmid">22557998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2012.00158</pub-id><pub-id pub-id-type="pmcid">PMC3339446</pub-id></element-citation></ref><ref id="B58-viruses-16-01476"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D.J.J.</given-names></name><name name-style="western"><surname>Gershburg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bertke</surname><given-names>A.S.</given-names></name></person-group><article-title>Assessment of two novel live-attenuated vaccine candidates for herpes simplex virus 2 (HSV-2) in guinea pigs</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>258</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9030258</pub-id><pub-id pub-id-type="pmid">33805768</pub-id><pub-id pub-id-type="pmcid">PMC7999511</pub-id></element-citation></ref><ref id="B59-viruses-16-01476"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Royer</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hendrix</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Larabee</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Reagan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sjoelund</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>D.J.J.</given-names></name></person-group><article-title>Vaccine-induced antibodies target sequestered viral antigens to prevent ocular HSV-1 pathogenesis, preserve vision, and preempt productive neuronal infection</article-title><source>Mucosal Immunol.</source><year>2019</year><volume>12</volume><fpage>827</fpage><lpage>839</lpage><pub-id pub-id-type="pmid">30670763</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41385-019-0131-y</pub-id><pub-id pub-id-type="pmcid">PMC6462227</pub-id></element-citation></ref><ref id="B60-viruses-16-01476"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meignier</surname><given-names>B.</given-names></name></person-group><article-title>Herpes simplex vaccines, current status and future prospects</article-title><source>Vaccine</source><year>1989</year><volume>7</volume><fpage>184</fpage></element-citation></ref><ref id="B61-viruses-16-01476"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halford</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Puschel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rakowski</surname><given-names>B.</given-names></name></person-group><article-title>Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: Implications for a genital herpes vaccine</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><elocation-id>e12251</elocation-id><pub-id pub-id-type="pmid">20808928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0012251</pub-id><pub-id pub-id-type="pmcid">PMC2923193</pub-id></element-citation></ref><ref id="B62-viruses-16-01476"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halford</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Puschel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gershburg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wilber</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gershburg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rakowski</surname><given-names>B.</given-names></name></person-group><article-title>A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e17748</elocation-id><pub-id pub-id-type="pmid">21412438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0017748</pub-id><pub-id pub-id-type="pmcid">PMC3055896</pub-id></element-citation></ref><ref id="B63-viruses-16-01476"><label>63.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Tumolo</surname><given-names>J.</given-names></name></person-group><article-title>Herpes Vaccines Shows Promise. Pharmacy Learning Network</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.hmpgloballearningnetwork.com/site/pln/content/herpes-vaccine-shows-promise" ext-link-type="uri">https://www.hmpgloballearningnetwork.com/site/pln/content/herpes-vaccine-shows-promise</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B64-viruses-16-01476"><label>64.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Keown</surname><given-names>A.</given-names></name></person-group><article-title>Rational&#8217;s Experimental Herpes Vaccine Shows Preclinical Promise. Biospace</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.biospace.com/study-rational-s-vaccine-reduces-herpes-simplex-lesions" ext-link-type="uri">https://www.biospace.com/study-rational-s-vaccine-reduces-herpes-simplex-lesions</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B65-viruses-16-01476"><label>65.</label><element-citation publication-type="webpage"><article-title>Rational Vaccines Receives UK MHRA Innovation Passport for RVx201 for the Treatment of Genital Herpes Resulting from Herpes Simplex Type 2 (HSV-2) Virus. PR Newswire</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.prnewswire.com/news-releases/rational-vaccines-receives-uk-mhra-innovation-passport-for-rvx201-for-the-treatment-of-genital-herpes-resulting-from-herpes-simplex-type-2-hsv-2-virus-301338810.html" ext-link-type="uri">https://www.prnewswire.com/news-releases/rational-vaccines-receives-uk-mhra-innovation-passport-for-rvx201-for-the-treatment-of-genital-herpes-resulting-from-herpes-simplex-type-2-hsv-2-virus-301338810.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B66-viruses-16-01476"><label>66.</label><element-citation publication-type="webpage"><article-title>Rational Vaccines Awarded $2.8 Million to Advance Groundbreaking Herpes Research</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.prnewswire.com/news-releases/rational-vaccines-awarded-2-8-million-to-advance-groundbreaking-herpes-research-301955530.html" ext-link-type="uri">https://www.prnewswire.com/news-releases/rational-vaccines-awarded-2-8-million-to-advance-groundbreaking-herpes-research-301955530.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-11">(accessed on 11 September 2024)</date-in-citation></element-citation></ref><ref id="B67-viruses-16-01476"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanfield</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Kousoulas</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gershburg</surname><given-names>E.</given-names></name></person-group><article-title>Rational design of live-attenuated vaccines against herpes simplex viruses</article-title><source>Viruses</source><year>2021</year><volume>13</volume><elocation-id>1637</elocation-id><pub-id pub-id-type="doi">10.3390/v13081637</pub-id><pub-id pub-id-type="pmid">34452501</pub-id><pub-id pub-id-type="pmcid">PMC8402837</pub-id></element-citation></ref><ref id="B68-viruses-16-01476"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernstein</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Pullum</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Cardin</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Bravo</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Dixon</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Kousoulas</surname><given-names>K.G.</given-names></name></person-group><article-title>The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>61</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">30471955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.11.042</pub-id></element-citation></ref><ref id="B69-viruses-16-01476"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanfield</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Rider</surname><given-names>P.J.F.</given-names></name><name name-style="western"><surname>Caskey</surname><given-names>J.</given-names></name><name name-style="western"><surname>Del Piero</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kousoulas</surname><given-names>K.G.</given-names></name></person-group><article-title>Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>2842</fpage><lpage>2849</lpage><pub-id pub-id-type="pmid">29655629</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.03.075</pub-id></element-citation></ref><ref id="B70-viruses-16-01476"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dropulic</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Oestreich</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Pietz</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Laing</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Hunsberger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lumbard</surname><given-names>K.</given-names></name><name name-style="western"><surname>Garabedian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Turk</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hornung</surname><given-names>R.L.</given-names></name><etal/></person-group><article-title>A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (HSV) type 2 Vvaccine, HSV529, in adults with or without HSV infection</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>990</fpage><lpage>1000</lpage><pub-id pub-id-type="pmid">31058977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiz225</pub-id><pub-id pub-id-type="pmcid">PMC6688060</pub-id></element-citation></ref><ref id="B71-viruses-16-01476"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dropulic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Oestreich</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pietz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Garabedian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jegaskanda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dowdell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Laing</surname><given-names>K.</given-names></name><name name-style="western"><surname>Koelle</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Replication-Defective Herpes Simplex Virus (HSV)-2 Vaccine, HSV529, is Safe and Well-Tolerated in Adults with or without HSV Infection and Induces Significant HSV-2-Specific Antibody Responses in HSV Seronegative Individuals</article-title><source>Open Forum Infect. Dis.</source><year>2017</year><volume>4</volume><issue>(Suppl. S1)</issue><fpage>S415</fpage><lpage>S416</lpage></element-citation></ref><ref id="B72-viruses-16-01476"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dutton</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Finlayson</surname><given-names>N.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>P.</given-names></name><name name-style="western"><surname>Frazer</surname><given-names>I.H.</given-names></name></person-group><article-title>An escalating dose study to assess the safety, tolerability and immunogenicity of a herpes simplex virus DNA vaccine, COR-1</article-title><source>Hum. Vaccin. Immunother.</source><year>2016</year><volume>12</volume><fpage>3079</fpage><lpage>3088</lpage><pub-id pub-id-type="pmid">27580249</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1221872</pub-id><pub-id pub-id-type="pmcid">PMC5215501</pub-id></element-citation></ref><ref id="B73-viruses-16-01476"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dutton</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tolley</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Yong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wells</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Leggatt</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Finlayson</surname><given-names>N.</given-names></name><etal/></person-group><article-title>DNA vaccine encoding HPV16 oncogenes E6 and E7 induces potent cell-mediated and humoral immunity which protects in tumor challenge and drives E7-expressing skin graft rejection</article-title><source>J. Immunother.</source><year>2017</year><volume>40</volume><fpage>62</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">28166181</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/CJI.0000000000000156</pub-id><pub-id pub-id-type="pmcid">PMC5293162</pub-id></element-citation></ref><ref id="B74-viruses-16-01476"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Park</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>M.S.</given-names></name><etal/></person-group><article-title>Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa</article-title><source>Antivir. Res.</source><year>2020</year><volume>177</volume><fpage>104755</fpage><pub-id pub-id-type="pmid">32112797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104755</pub-id></element-citation></ref><ref id="B75-viruses-16-01476"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hook</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cairns</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Alameh</surname><given-names>M.-G.</given-names></name><name name-style="western"><surname>Fowler</surname><given-names>B.T.</given-names></name><name name-style="western"><surname>Egan</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>M.M.H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>Antibodies to crucial epitopes on HSV-2 glycoprotein D as a guide to dosing an mRNA genital herpes vaccine</article-title><source>Viruses</source><year>2022</year><volume>14</volume><elocation-id>540</elocation-id><pub-id pub-id-type="doi">10.3390/v14030540</pub-id><pub-id pub-id-type="pmid">35336946</pub-id><pub-id pub-id-type="pmcid">PMC8953786</pub-id></element-citation></ref><ref id="B76-viruses-16-01476"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>An mRNA vaccine to prevent genital herpes</article-title><source>Transl. Res.</source><year>2022</year><volume>242</volume><fpage>56</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">34954087</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2021.12.006</pub-id><pub-id pub-id-type="pmcid">PMC8695322</pub-id></element-citation></ref><ref id="B77-viruses-16-01476"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Egan</surname><given-names>K.P.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Naughton</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008795</elocation-id><pub-id pub-id-type="pmid">32716975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008795</pub-id><pub-id pub-id-type="pmcid">PMC7410331</pub-id></element-citation></ref><ref id="B78-viruses-16-01476"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Pahar</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stagray</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Veazey</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>An HSV-2 Trivalent Vaccine Is Immunogenic in Rhesus Macaques and Highly Efficacious in Guinea Pigs</article-title><source>PLoS Pathog.</source><year>2017</year><volume>13</volume><elocation-id>e1006141</elocation-id><pub-id pub-id-type="pmid">28103319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1006141</pub-id><pub-id pub-id-type="pmcid">PMC5245903</pub-id></element-citation></ref><ref id="B79-viruses-16-01476"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Awasthi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hook</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Myles</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cancro</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>H.M.</given-names></name></person-group><article-title>Nucleoside-modified mRNA encoding HSV-2 glycoproteins C, D, and E prevents clinical and subclinical genital herpes</article-title><source>Sci. Immunol.</source><year>2019</year><volume>4</volume><fpage>eaaw7083</fpage><pub-id pub-id-type="pmid">31541030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.aaw7083</pub-id><pub-id pub-id-type="pmcid">PMC6822172</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01476-f001" orientation="portrait"><label>Figure 1</label><caption><p>The structure of HSV virion and a schematic of HSV genome. (<bold>A</bold>) The HSV virion consists of a linear double-stranded DNA genome enclosed within an icosahedral capsid. Tegument proteins are distributed between the capsid and the lipid bilayer envelope. Glycoproteins are embedded in the outer surface of the envelope, facilitating viral entry (key glycoproteins in vaccine targeting include gB, gC, gD, and gE). (<bold>B</bold>) The HSV-1 genome schematic includes unique long (U<sub>L</sub>) and unique short (U<sub>S</sub>) regions, which are flanked by internal or terminal repeats, (IR<sub>L</sub> and TR<sub>L</sub>) and (IR<sub>S</sub> and TR<sub>S</sub>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-16-01476-g001.jpg"/></fig><fig position="float" id="viruses-16-01476-f002" orientation="portrait"><label>Figure 2</label><caption><p>HSV defense mechanisms to evade intrinsic and adaptive immune responses. cGAS (cyclic GMP-AMP synthase); IFN (interferon); IKK (inhibitor of &#954;B kinase); IRF3 (interferon regulatory factor 3); NEMO (nuclear factor-kappa B essential modulator); NF-&#954;B (Nuclear Factor-kappa B); I&#954;B&#945; (NF-&#954;B inhibitor alpha); STING (stimulator of interferon genes); TAK1 (transforming growth factor-&#946;-activated kinase 1; TBK1 (tank-binding kinase 1).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-16-01476-g002.jpg"/></fig><table-wrap position="float" id="viruses-16-01476-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-16-01476-t001_Table 1</object-id><label>Table 1</label><caption><p>Clinically relevant HSV vaccines in articles screened from PubMed, EMBASE, Medline, and Google Scholar.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Type</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Vaccine Candidate</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antigen</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant/Route of Administration</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Attenuation</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Results</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Refs</th></tr></thead><tbody><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Subunit </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GEN-003 (from Genocea)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gD2/ICP4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Matrix M2; arm muscle injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unsatisfactory phase 2 results. Further development was abandoned.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B47-viruses-16-01476" ref-type="bibr">47</xref>,<xref rid="B48-viruses-16-01476" ref-type="bibr">48</xref>,<xref rid="B49-viruses-16-01476" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01476" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VCL-HB01 (Vical)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gD2 and VP11/12 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unsatisfactory phase 2 results. Further development was abandoned.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B51-viruses-16-01476" ref-type="bibr">51</xref>,<xref rid="B52-viruses-16-01476" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HerpV (from Agenus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 peptides + HSP70 chaperone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">QS-21; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reported to reduce viral shedding in HSV-2-infected subjects by approximately 15% after boost immunization. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B53-viruses-16-01476" ref-type="bibr">53</xref>,<xref rid="B54-viruses-16-01476" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Simplirix (GlaxoSmithKline; Herpevac Trial for Women)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-2 gD2 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MLA; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Inactive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three vaccine doses were 58% protective against culture-positive HSV-1 genital disease but did not protect against HSV-2.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B55-viruses-16-01476" ref-type="bibr">55</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Live-attenuated replication-competent </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HF10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A live-attenuated, replication-competent HSV-1 naturally mutated (i.e., not engineered)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naturally mutated for <italic toggle="yes">UL43</italic>, <italic toggle="yes">UL49.5</italic>, <italic toggle="yes">UL55</italic>, <italic toggle="yes">UL56</italic>, <italic toggle="yes">LAT</italic> genes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunization with HF10 protected mice against clinical symptoms elicited by HSV-2 inhibited HSV-2 replication at the site of virus introduction, reduced local inflammation, blocked neuroinvasion, and increased survival.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B56-viruses-16-01476" ref-type="bibr">56</xref>,<xref rid="B57-viruses-16-01476" ref-type="bibr">57</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0&#916;NLS (RVx201)<break/>(Rational Vaccines)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ICP0 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Alum, lipid A; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeted mutations within full-length ICP0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Superior effectiveness of gD2 vaccines at protecting guinea pigs from lethal challenges. Conferred immunity to ocular HSV-1 challenge (pathology-free corneas) with reduced infection of the nervous system. Preclinical trials show good efficacy.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B58-viruses-16-01476" ref-type="bibr">58</xref>,<xref rid="B59-viruses-16-01476" ref-type="bibr">59</xref>,<xref rid="B60-viruses-16-01476" ref-type="bibr">60</xref>,<xref rid="B61-viruses-16-01476" ref-type="bibr">61</xref>,<xref rid="B62-viruses-16-01476" ref-type="bibr">62</xref>,<xref rid="B63-viruses-16-01476" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01476" ref-type="bibr">64</xref>,<xref rid="B65-viruses-16-01476" ref-type="bibr">65</xref>,<xref rid="B66-viruses-16-01476" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VC2 (HSV-1) (Rational Vaccines)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletions of gK aa31-68 and UL20 aa4-22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Decreased clinical severity of acute and recurrent HSV-2 disease and shedding. Decreased dorsal root ganglion viral load in guinea pigs. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-viruses-16-01476" ref-type="bibr">67</xref>,<xref rid="B68-viruses-16-01476" ref-type="bibr">68</xref>,<xref rid="B69-viruses-16-01476" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replication-defective </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV529 (Sanofi Pasteur)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">None; intramuscular injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deletions of UL5 and UL29</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1: 64% of vaccine vs. 53% of placebo recipients had systemic reactions. Serum and vaginal antibodies to HSV-2 glycoprotein D (gD) significantly increased after 3 doses.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-viruses-16-01476" ref-type="bibr">70</xref>,<xref rid="B71-viruses-16-01476" ref-type="bibr">71</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">COR-1 (Anteris Technologies, formerly Admedus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Codon-modified full-length HSV-2 gD2 and ubiquitin-fused truncated gD2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaxfectin; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Achieved safety, tolerability, and immunogenicity phase I endpoints. While antibody responses were not observed, cell-mediated immunity was demonstrated. </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B72-viruses-16-01476" ref-type="bibr">72</xref>,<xref rid="B73-viruses-16-01476" ref-type="bibr">73</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SL-V20 (SL VAXiGEN)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-2 gB, gD2, and UL39 plasmid DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cytokines; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preclinical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% mouse survival from lethal challenge. T cell-mediated protective response (B cells were dispensable).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B74-viruses-16-01476" ref-type="bibr">74</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-1608-P101 (Moderna)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HSV-2 gC2, gD2, gE2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lipid nanoparticles; injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100% mouse and guinea pig survival upon lethal challenge. Reduced animal genital disease by 85&#8211;100%. Outperformed a protein form of the same vaccine.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B75-viruses-16-01476" ref-type="bibr">75</xref>,<xref rid="B76-viruses-16-01476" ref-type="bibr">76</xref>,<xref rid="B77-viruses-16-01476" ref-type="bibr">77</xref>,<xref rid="B78-viruses-16-01476" ref-type="bibr">78</xref>,<xref rid="B79-viruses-16-01476" ref-type="bibr">79</xref>]</td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>